{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:30Z","timestamp":1792036830466,"version":"4.4.0"},"reference-count":31,"publisher":"Hindawi Limited","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":182,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Ther"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1111\/dth.12222","type":"journal-article","created":{"date-parts":[[2015,3,3]],"date-time":"2015-03-03T06:48:55Z","timestamp":1425365335000},"page":"158-165","source":"Crossref","is-referenced-by-count":88,"title":["Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients"],"prefix":"10.1155","volume":"28","author":[{"given":"Freja Laerke","family":"Sand","sequence":"first","affiliation":[{"name":"Department of Dermatology; Bispebjerg Hospital; University of Copenhagen; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Francis","family":"Thomsen","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Bispebjerg Hospital; University of Copenhagen; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2015,3,3]]},"reference":[{"key":"10.1111\/dth.12222-BIB0001|dth12222-cit-0001","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1517\/14712598.2011.590798","article-title":"Tumor necrosis factor biologics beyond psoriasis in dermatology","volume":"11","author":"Patel","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1111\/dth.12222-BIB0002|dth12222-cit-0002","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3109\/09546634.2013.800633","article-title":"Efficacy and safety of TNF-alpha inhibitors in refractory primary complex aphthosis: a patient series and overview of the literature","volume":"24","author":"Sand","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/dth.12222-BIB0003|dth12222-cit-0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/130905","article-title":"TNF-alpha inhibitors for chronic urticaria: experience in 20 patients","volume":"2013","author":"Sand","year":"2013","journal-title":"J Allergy"},{"key":"10.1111\/dth.12222-BIB0004|dth12222-cit-0004","first-page":"1306","article-title":"Adalimumab for treatment of refractory acne conglobata","volume":"149","author":"Sand","year":"2013","journal-title":"JAMA"},{"key":"10.1111\/dth.12222-BIB0005|dth12222-cit-0005","article-title":"Adherence to TNF-alpha inhibitors in patients with hidradenitis suppurativa","author":"Thomsen","year":"2014","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/dth.12222-BIB0006|dth12222-cit-0006","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1468-3083.2011.04041.x","article-title":"Efficacy of tumour necrosis factor-alpha antagonists in aphthous ulceration: review of published individual patient data","volume":"26","author":"O'Neill","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl. 2","key":"10.1111\/dth.12222-BIB0007|dth12222-cit-0007","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.61.suppl_2.ii51","article-title":"Behcet's disease: a new target for anti-tumor necrosis factor treatment","volume":"61","author":"Sfikasis","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/dth.12222-BIB0008|dth12222-cit-0008","first-page":"128","article-title":"Systemic levels of the T cell regulatory cytokines IL-10 and IL-2 in Behcet's disease: soluble TNFR-75 as a biological marker of disease activity","volume":"24","author":"Turan","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1111\/dth.12222-BIB0009|dth12222-cit-0009","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000058004","article-title":"Immune profiles of patients with chronic urticaria","volume":"128","author":"Piconi","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1111\/dth.12222-BIB0010|dth12222-cit-0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0091-6749(99)70506-3","article-title":"Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria","volume":"103","author":"Hermes","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/dth.12222-BIB0011|dth12222-cit-0011","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2340\/00015555-0749","article-title":"Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents?","volume":"89","author":"Matusiak","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/dth.12222-BIB0012|dth12222-cit-0012","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1 beta","volume":"164","author":"Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/dth.12222-BIB0013|dth12222-cit-0013","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3109\/09546634.2012.674193","article-title":"The off-label treatment of severe hidradenitis suppurativa with TNF-alpha inhibitors: a systematic review","volume":"24","author":"Rappard","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/dth.12222-BIB0014|dth12222-cit-0014","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1046\/j.1365-2133.2004.05762.x","article-title":"Proinflammatory cytokine production by human keratinocytes stimulated by Propionibacterium acnes and P. acnes GroEL","volume":"150","author":"Graham","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1111\/dth.12222-BIB0015|dth12222-cit-0015","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/j.1572-0241.2003.07581.x","article-title":"Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease","volume":"98","author":"Regueiro","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/dth.12222-BIB0016|dth12222-cit-0016","first-page":"441","article-title":"Treatment of pyoderma gangrenosum with etanercept","volume":"3","author":"McGowan","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/dth.12222-BIB0017|dth12222-cit-0017","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1365-2133.2005.06467.x","article-title":"Systemic pyoderma gangrenosum responding to infliximab and adalimumab","volume":"152","author":"Hubbard","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/dth.12222-BIB0018|dth12222-cit-0018","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/j.jaad.2005.11.1089","article-title":"Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept","volume":"54","author":"Yamauchi","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/dth.12222-BIB0019|dth12222-cit-0019","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3899\/jrheum.080698","article-title":"Etanercept treatment in Sweet's syndrome with inflammatory arthritis","volume":"36","author":"Ambrose","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1111\/dth.12222-BIB0020|dth12222-cit-0020","first-page":"376","article-title":"Regression of Sweet's syndrome associated with Crohn's disease after anti-tumour necrosis factor therapy","volume":"68","author":"Rahier","year":"2005","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1111\/dth.12222-BIB0021|dth12222-cit-0021","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-2141.1993.tb03083.x","article-title":"Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease","volume":"84","author":"Reuss-Borst","year":"1993","journal-title":"Br J Haematol"},{"key":"10.1111\/dth.12222-BIB0022|dth12222-cit-0022","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/archderm.137.12.1571","article-title":"Infliximab (anti-tumor necrosis alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustulosis (Sneddon-Wilkinson disease)","volume":"137","author":"Voigtl\u00e4nder","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1111\/dth.12222-BIB0023|dth12222-cit-0023","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2230.2008.02905.x","article-title":"Sneddon-Wilkinson disease treated with etanercept: report of two cases","volume":"34","author":"Berk","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/dth.12222-BIB0024|dth12222-cit-0024","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/0190-9622(91)70290-I","article-title":"Role of tumor necrosis alpha in Sneddon-Wilkinson subcorneal pustular dermatosis. A model of neutrophilic priming in vivo","volume":"25","author":"Grob","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/dth.12222-BIB0025|dth12222-cit-0025","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jaad.2012.10.056","article-title":"A double-blind, randomized, placebo-controlled trail of adalimumab in the treatment of cutaneous sarcoidosis","volume":"68","author":"Pariser","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/dth.12222-BIB0026|dth12222-cit-0026","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1365-4632.2010.04507.x","article-title":"Successful treatment of granulomatous cheilitis with adalimumab","volume":"51","author":"Ruiz Villaverde","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1111\/dth.12222-BIB0027|dth12222-cit-0027","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2340\/00015555-0219","article-title":"Infliximab: a novel treatment option for refractory orofacial granulomatosis","volume":"87","author":"Peitsch","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/dth.12222-BIB0028|dth12222-cit-0028","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/gut.2006.099143","article-title":"Anti-TNF-alpha therapy for orofacial granulomatosis: proceed with caution","volume":"55","author":"Gaya","year":"2006","journal-title":"Gut"},{"key":"10.1111\/dth.12222-BIB0029|dth12222-cit-0029","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/archderm.141.9.1080","article-title":"Treatment of granulomatous cheilitis with infliximab","volume":"141","author":"Barry","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1111\/dth.12222-BIB0030|dth12222-cit-0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1081-1206(10)60643-6","article-title":"Melkersson-Rosenthal syndrome: a form of pseudoangioedema","volume":"99","author":"Kakimoto","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1111\/dth.12222-BIB0031|dth12222-cit-0031","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/j.jaad.2005.11.1090","article-title":"Case reposts of etanercept in inflammatory dermatoses","volume":"54","author":"Norman","year":"2006","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdth.12222","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/dth.12222\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T14:59:22Z","timestamp":1691506762000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dth.12222"}},"subtitle":["Off-label use of TNF-alpha inhibitors"],"short-title":[],"issued":{"date-parts":[[2015,3,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,5]]}},"URL":"https:\/\/doi.org\/10.1111\/dth.12222","relation":{},"ISSN":["1396-0296"],"issn-type":[{"value":"1396-0296","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3,3]]}}}